Stockholm based Guard Therapeutics is trying to harness the natural properties of A1M (alpha-1-microglobulin) to protect the kidney

blonca9
Sep 21, 2024
1 min read

CEO Tobias Agervald explains how the lead program RMC-035 is being tested in conjunction with open heart surgery while smaller fragments of A1M are being developed for chronic kidney disease.

Recent Posts

See All

Checking in with MoonLake's CEO ahead of one of biotech's most closely watched trial readouts of the year - the phase 3 VELA program of sonelokimab in HS (due in Sept)

KalVista's CEO discusses today's FDA approval and commercial launch of Ekterly, the first oral therapy for treating hereditary angioedema (HAE) attacks

AI News: Singapore based Gero, a company focused on small molecules for aging conditions, launched ProtoBind-Diff, a model using amino acid sequences rather than structure models for discovery

Stockholm based Guard Therapeutics is trying to harness the natural properties of A1M (alpha-1-microglobulin) to protect the kidney

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight